All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Patients with type 2 diabetes mellitus (DM) may exhibit impaired insulin secretion and insulin resistance. While multifaceted pathophysiological abnormalities of pancreatic islet cells are known to be involved in progressive deterioration of beta-cell mass and function in DM patients \[[@pone.0236603.ref001]--[@pone.0236603.ref004]\], debates continue on whether some hypoglycemic drugs may have pancreatic beta-cell function preserving effects. There is a possibility that dipeptidyl peptidase-4 (DPP-4) inhibitors may slow deterioration of beta-cell function in patients with type 2 DM, since administration of these drugs increased or restored the pancreatic beta-cell mass in mice and rats \[[@pone.0236603.ref005]--[@pone.0236603.ref007]\]. At present, however, it remains unclear whether DPP-4 inhibitors have advantage over other hypoglycemic drugs by exhibiting pancreatic beta-cell function preserving effect.

While many biomarkers have been proposed for quantifying *in vivo* pancreatic beta-cell function, the homeostatic model of assessment of beta-cell function (HOMA-β) has been employed most frequently in epidemiological studies \[[@pone.0236603.ref008]\]. Recently, the proinsulin-to-insulin ratio (PIR) has also been used in many studies as a biomarker of beta-cells \[[@pone.0236603.ref009], [@pone.0236603.ref010]\]. While HOMA-β may be associated with insulin secretion or beta-cell mass \[[@pone.0236603.ref011]\], PIR may reflect the efficiency of proinsulin processing within beta-cells \[[@pone.0236603.ref012]\]. As a result, it is of interest to study whether the two biomarkers show similar or different changes over time after initiation of hypoglycemic drugs with different mechanisms of action in patients with type 2 DM.

Previous studies using mainly HOMA-β as biomarker demonstrated that DPP-4 inhibitors may have greater pancreatic beta-cell function preserving effect compared with placebo in patients with type 2 DM \[[@pone.0236603.ref010], [@pone.0236603.ref013]--[@pone.0236603.ref016]\]. Many pair-wise comparisons of DPP-4 inhibitors with α-glucosidase inhibitors (α-GIs), metformin or sulfonylureas using various biomarkers have been reported \[[@pone.0236603.ref017]--[@pone.0236603.ref020]\]. However, none of the previous studies in patients with type 2 DM compared the pancretic beta-cell function preserving effect between DPP-4 inhibitors and other classes of hypoglycemic drugs using both HOMA-β and PIR as biomarkers. Here, we present our results of a meta-analysis that cast doubt about interpretationg epidemiologic data based on assessment by HOMA-β alone.

Materials and methods {#sec006}
=====================

The present study was performed according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses ([S1 Table](#pone.0236603.s003){ref-type="supplementary-material"}) \[[@pone.0236603.ref021]\].

Curation of literature {#sec007}
----------------------

We searched for relevant studies using MEDLINE (from 1966 to May 2020), Cochrane Central Register of Controlled Trials (CENTRAL, Issue 5 of 12, May 2020), and Ichushi-web (Japan Medical Abstracts Society, from 1983 to May 2020). The search formula consisted of generic names of the seven DPP-4 inhibitors (alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin, and vildagliptin) AND (diabetes mellitus \[all fields\]) AND (Randomized Controlled Trial \[publication type\]). The detailed search strategies for each database were shown in [S2 Table](#pone.0236603.s004){ref-type="supplementary-material"}. Further search was performed using information available from the references of the retrieved studies, where necessary.

Inclusion criteria were: (1) studies were written in English or Japanese; (2) patients with type 2 DM were studied; (3) changes in HOMA-β and/or PIR from the beginning to the end of study were available; (4) comparisons of biomarkers were made between one of the seven DPP-4 inhibitors and another class of hypoglycemic agent \[α-GIs, GLP-1 analogues, metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, sulfonylureas, or thiazolidinediones\]; and (5) studies had a prospective and randomized design. When biomarkers were measured more than once during the study period, or interim and final reports of a study were published independently, we only used the data having the longest follow-up period for that study. Inclusion of individual studies in the meta-analysis was decided by two independent reviewers (MT and MS) according to the above inclusion criteria. In the case of disagreement between two reviewers on the decision of inclusion, the difference was resolved by discussion.

Biomarkers {#sec008}
----------

HOMA-β (%) was calculated according to the following equation: (20 × insulin \[μU/mL\])/(glucose \[mmol/L\]-- 3.5) \[[@pone.0236603.ref022]\], or by computer program \[[@pone.0236603.ref023]\]. HOMA-β values are known to be reduced in patients with type 2 DM, and the reduction is considered to be associated with pancreatic beta-cell dysfunction. PIR was calculated as serum proinsulin level divided by insulin level. When PIR was given as (pmol/L)/(μU/mL), the value was divided by 7.175 \[[@pone.0236603.ref024]\] and converted to dimensionless value. Elevated PIR has also been known to be another biomarker of beta-cell dysfunction.

Data analysis {#sec009}
-------------

Mean and standard deviation (SD) of within-patient changes in HOMA-β and/or PIR from baseline to the end of study were computed from the curated data (numerical data in tables or text). When only graphical presentations of the data were available, relevant data points were converted to digital data using UnGraph ver. 5 digitizer program (BIOSOFT, Cambridge, United Kingdom), which gives X and Y coordinates of lines and points on scanned images. When multiple doses of a DPP-4 inhibitor were given to different groups of patients, the data obtained from patients given doses that are approved in Japan were used for analysis. When data of biomarkers at baseline and at the end of study were available only as group mean values (not as within-patient changes), we substituted within-group changes by within-patient changes. We also estimated SD of the within-patient changes according to the equation reported elsewhere \[[@pone.0236603.ref025]\]. $$\text{SD} = \sqrt{\frac{\text{SD}_{\text{before}}^{2}}{\text{N}_{\text{before}}} + \frac{\text{SD}_{\text{after}}^{2}}{\text{N}_{\text{after}}}} \times \sqrt{\text{N}_{\text{before}} + \text{N}_{\text{after}}}$$ where N~before~ and N~after~ are the numbers of patients before and after intervention, and SD~before~ and SD~after~ are the SD of the group before and after intervention, respectively. When no SD was given in the original study and only 95% CI was given, we estimated the corresponding SD values according to the equation given below \[[@pone.0236603.ref026]\]: $$\text{SD} = \sqrt{\text{N}} \times \left( {\text{upper}\ \text{limit} - \text{lower}\ \text{limit}} \right) \times \frac{1}{3.92}$$ For statistical analysis of meta-analysis, we calculated weighted mean differences (WMDs) of HOMA-β or PIR for DPP-4 inhibitor groups versus comparator drug groups, and the 95% confidence intervals (CIs).

We compared the pancreatic beta-cell function preserving effects of various hypoglycemic drugs using DPP-4 inhibitors as reference. Changes in mean HOMA-β during the study period obtained from hypoglycemic drugs other than DPP-4 inhibitors (such as GLP-1 analogues) were subtracted from the value obtained from DPP-4 inhibitors. Consequently, when the calculated value was positive, the DPP-4 inhibitor was considered to have greater beta-cell preserving effect than the comparator. For the comparisons of PIR, however, when the calculated value was negative, the DPP-4 inhibitor was considered to have greater effect than the comparator.

Besides HOMA-β and PIR, mean values of patients' demographic data and clinical characteristics \[including body mass index (BMI), glycosylated hemoglobin A1c (HbA1c) (%), and duration since diagnosis of type 2 DM\] were curated for assessment of comparability of trials. Quality of study was assessed using the risk of bias tool provided by the Cochrane Handbook \[[@pone.0236603.ref027]\]. Two reviewers (MT and MS) independently evaluated all studies according to the following seven critical items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias (i.e., enough patients enrolled to reach the endpoint, adequate compliance). Publication bias was assessed visually using funnel plots and statistically using the method of Egger et al. \[[@pone.0236603.ref028]\]. Heterogeneity of curated data from individual studies was examined by Cochrane's Q test. When an I^2^ value exceeded 50%, we considered that there was heterogeneity between the studies analyzed. We used fixed effects model when heterogeneity of curated data was rejected, and used a random effects model otherwise. For statistical analysis of meta-analysis, we calculated WMDs and their 95% CIs using Review Manager version 5.3 (The Nordic Cochrane Centre, the Cochrane Collaboration, Copenhagen, Denmark) based on an inverse variance method.

For sensitivity analyses, studies considered having high risk of bias in at least two out of seven domains (such as unblinded participants or personnel) were removed, and then analyses were repeated. In addition, we performed sensitivity tests when funnel plots of meta-analysis data suggested a possibility of publication bias. Specifically, we excluded suspected studies one by one from the corresponding meta-analysis and examined if there was a qualitative change in the result of statistical inference. When the statistical significance was lost by exclusion of a specific study, we considered that the result of the corresponding meta-analysis was conditional.

We presented the results of meta-analyses in a two-dimensional plot, in which we plotted the WMDs with 95% CIs obtained from comparisons of DPP-4 inhibitors versus other classes of hypoglycemia drugs (comparators: α-GIs, GLP-1 analogues, metformin, SGLT2 inhibitors, sulfonylureas, and thiazolidinediones) using HOMA-β (ordinate) and PIR (abscissa) as biomarkers. In addition, we depicted the approximate sample size of each comparison by the area of a circle in the plot.

Results {#sec010}
=======

Characteristics of the included studies {#sec011}
---------------------------------------

In this meta-analysis, we retrieved 40 relevant studies from the three databases; MEDLINE, CENTRAL, and Ichushi-web, as shown in the flowchart ([Fig 1](#pone.0236603.g001){ref-type="fig"}). Among these studies, data for analysis were available for six of seven DPP-4 inhibitors: alogliptin (n = 2) \[[@pone.0236603.ref029], [@pone.0236603.ref030]\], anagliptin (n = 1) \[[@pone.0236603.ref031]\], linagliptin (n = 3) \[[@pone.0236603.ref032]--[@pone.0236603.ref034]\], saxagliptin (n = 4) \[[@pone.0236603.ref035]--[@pone.0236603.ref038]\], sitagliptin (n = 26) \[[@pone.0236603.ref039]--[@pone.0236603.ref064]\], and vildagliptin (n = 4) \[[@pone.0236603.ref065]--[@pone.0236603.ref068]\], but not for teneligliptin (n = 0). Comparators of DPP-4 inhibitors were α-GIs (n = 9) \[[@pone.0236603.ref030], [@pone.0236603.ref031], [@pone.0236603.ref034], [@pone.0236603.ref035], [@pone.0236603.ref041], [@pone.0236603.ref050], [@pone.0236603.ref063]--[@pone.0236603.ref065]\], GLP-1 analogues (n = 5) \[[@pone.0236603.ref047], [@pone.0236603.ref052], [@pone.0236603.ref058], [@pone.0236603.ref062], [@pone.0236603.ref068]\], metformin (n = 5) \[[@pone.0236603.ref029], [@pone.0236603.ref038]--[@pone.0236603.ref040], [@pone.0236603.ref056]\], SGLT2 inhibitors (n = 5) \[[@pone.0236603.ref036], [@pone.0236603.ref053], [@pone.0236603.ref054], [@pone.0236603.ref060], [@pone.0236603.ref061]\], sulfonylureas (n = 12) \[[@pone.0236603.ref032], [@pone.0236603.ref033], [@pone.0236603.ref037], [@pone.0236603.ref043]--[@pone.0236603.ref046], [@pone.0236603.ref048], [@pone.0236603.ref057], [@pone.0236603.ref059], [@pone.0236603.ref066], [@pone.0236603.ref067]\], and thiazolidinediones (n = 4) \[[@pone.0236603.ref042], [@pone.0236603.ref049], [@pone.0236603.ref051], [@pone.0236603.ref055]\].

![Flowchart displaying the steps of selection of studies on seven dipeptidyl peptidase-4 inhibitors for meta-analysis.\
Numbers of articles that met either the inclusion or exclusion criteria are shown in small tables. Abbreviations: CEN, CENTRAL; IW, Ichushi-web; MED, MEDLINE; MS, manual search.](pone.0236603.g001){#pone.0236603.g001}

A concise summary of the studies included in the meta-analysis was shown in [Table 1](#pone.0236603.t001){ref-type="table"}. The overall mean HOMA-β at baseline was 55.9% (range: 25.5% to 150.6%), and mean PIR was 0.35 (range: 0.20 to 0.60). The mean follow-up period was 34 weeks (range: 8 to 104 weeks). As for the quality of studies, 11 studies \[[@pone.0236603.ref035], [@pone.0236603.ref038], [@pone.0236603.ref050], [@pone.0236603.ref052], [@pone.0236603.ref055], [@pone.0236603.ref057], [@pone.0236603.ref059], [@pone.0236603.ref061], [@pone.0236603.ref063], [@pone.0236603.ref066], [@pone.0236603.ref068]\] were considered at high risk of bias according to the tool of Cochrane Handbook. All 11 were open label studies ([S3 Table](#pone.0236603.s005){ref-type="supplementary-material"}). Particularly, two studies were considered to be at high risk of bias in three domains \[[@pone.0236603.ref050], [@pone.0236603.ref063]\]. Both studies compared the clinical outcomes between sitagliptin and α-GIs, and adherence was significantly lower in the α-GIs group than in the sitagliptin group.

10.1371/journal.pone.0236603.t001

###### Summary of studies included in the meta-analysis.

![](pone.0236603.t001){#pone.0236603.t001g}

  Study                                               Follow -up, weeks   Mean age, years   Mean BMI, kg/m^2^   Mean baseline HbA1c, %   Mean T2DM duration, years   Mean baseline HOMA-β %   Mean baseline PIR   Add-on therapy                        DPP-4 inhibitor dose       No. of subjects in DPP-4 inhibitor group   Comparator drug dose                         No. of subjects in comparator drug group   Outcome   
  --------------------------------------------------- ------------------- ----------------- ------------------- ------------------------ --------------------------- ------------------------ ------------------- ------------------------------------- -------------------------- ------------------------------------------ -------------------------------------------- ------------------------------------------ --------- ---
  Pratley 2014 \[[@pone.0236603.ref029]\]             28                  53.6              30.5                NR                       3.7                         71.3                     0.30                No                                    Alogliptin 25 mg qd        112                                        Metformin 500 mg bid                         114                                        ✓         ✓
  Seino 2011 \[[@pone.0236603.ref030]\]               12                  59.3              25.0                7.9                      6.4                         NR                       NR                  No                                    Alogliptin 25 mg qd        80                                         Voglibose 0.2 mg tid                         83                                         ✓         
  Kaku 2012 \[[@pone.0236603.ref031]\]                12                  59.0              24.6                7.7                      8.0                         30.6                     NR                  No                                    Anagliptin 100 mg bid      63                                         Voglibose 0.2 mg tid                         65                                         ✓         ✓
  Forst 2010 \[[@pone.0236603.ref032]\]               12                  59.5              31.6                8.4                      7.0                         NR                       0.20                Metformin                             Linagliptin 5 mg qd        66                                         Glimepiride 1--3 mg qd                       65                                                   ✓
  Gallwitz 2012 \[[@pone.0236603.ref033]\]            104                 59.8              30.2                7.7                      \> 5.0 (≥ 50% subjects)     NR                       NR                  Metformin                             Linagliptin 5 mg qd        776                                        Glimepiride 1--4 mg qd                       775                                                  ✓
  Kawamori 2012 \[[@pone.0236603.ref034]\]            26                  59.4              25.2                8.0                      \> 5.0 (≥ 49% subjects)     NR                       0.27                No                                    Linagliptin 5 mg qd        159                                        Voglibose 0.2 mg tid                         162                                                  ✓
  Du 2017 \[[@pone.0236603.ref035]\]                  24                  55.6              26.3                8.2                      5.2                         55.5                     NR                  Metformin                             Saxagliptin 5 mg qd        238                                        Acarbose 50--100 mg tid                      243                                        ✓         
  Ekholm 2017 \[[@pone.0236603.ref036]\]              24                  54.5              31.5                8.9                      7.7                         40.3                     NR                  Metformin                             Saxagliptin 5 mg qd        154                                        Dapagliflozin 10 mg qd                       152                                        ✓         
  Göke 2010 \[[@pone.0236603.ref037]\]                52                  57.6              31.4                7.7                      5.4                         67.5                     NR                  Metformin                             Saxagliptin 5 mg qd        428                                        Glipizide 5--20 mg qd                        430                                        ✓         
  Tao 2018 \[[@pone.0236603.ref038]\]                 24                  29.0              26.8                7.4                      0                           150.6                    NR                  No                                    Saxagliptin 5 mg qd        21                                         Metformin 2000 mg qd                         21                                         ✓         
  Aschner 2010 \[[@pone.0236603.ref039]\]             24                  56.0              30.8                7.2                      2.4                         85.4                     0.31                No                                    Sitagliptin 100 mg qd      455                                        Metformin 1000 mg bid                        439                                        ✓         ✓
  Berg 2011 \[[@pone.0236603.ref047]\]                8                   54.5              34.9                8.3                      7.5                         53.5                     NR                  Metformin or thiazolidinediones       Sitagliptin 100 mg qd      42                                         Exenatide 5--10 μg bid                       41                                         ✓         
  Derosa 2010 \[[@pone.0236603.ref040]\]              52                  57.5              27.8                8.5                      5.5                         53.3                     0.38                Pioglitazone                          Sitagliptin 100 mg qd      75                                         Metformin 850 mg bid                         76                                         ✓         ✓
  Derosa 2013 \[[@pone.0236603.ref048]\]              52                  NR                27.5                7.2                      NR                          93.0                     0.25                Metformin + pioglitazone              Sitagliptin 100 mg qd      228                                        Glibenclamide 5 mg tid                       225                                        ✓         ✓
  Arjona 2013a \[[@pone.0236603.ref045]\]             54                  59.5              26.8                7.9                      17.5                        NR                       NR                  No                                    Sitagliptin 25 mg qd       64                                         Glipizide 2.5 mg qd-10 mg bid                65                                         ✓         ✓
  Arjona 2013b \[[@pone.0236603.ref046]\]             54                  64.5              26.8                7.8                      10.4                        NR                       NR                  No                                    Sitagliptin 25--50 mg qd   135                                        Glipizide 2.5 mg qd-10 mg bid                142                                        ✓         ✓
  Fukui 2015 \[[@pone.0236603.ref057]\]               24                  66.3              26.3                7.4                      7.5                         60.9                     0.49                Sulfonylurea                          Sitagliptin 50 mg qd       21                                         Sulfonylurea dose not reported               22                                         ✓         ✓
  Gadde 2017 \[[@pone.0236603.ref058]\]               28                  53.8              31.9                8.4                      8.3                         45.5                     NR                  Metformin                             Sitagliptin 100 mg qd      122                                        Exenatide 2.0 mg qw                          181                                        ✓         
  Henry 2014 \[[@pone.0236603.ref049]\]               54                  51.8              31.3                8.8                      4.1                         68.7                     0.37                No                                    Sitagliptin 100 mg qd      186                                        Pioglitazone 45 mg qd                        188                                        ✓         ✓
  Iwamoto 2010 \[[@pone.0236603.ref041]\]             12                  60.7              24.7                7.8                      5.2                         35.5                     NR                  No                                    Sitagliptin 50 mg qd       163                                        Voglibose 0.2 mg tid                         156                                        ✓         
  Kobayashi 2014 \[[@pone.0236603.ref050]\]           24                  64.2              24.2                7.7                      8.6                         39.1                     NR                  Glimepiride                           Sitagliptin 50 mg qd       59                                         Voglibose 0.2 mg tid or miglitol 50 mg tid   55                                         ✓         ✓
  Park 2017 \[[@pone.0236603.ref059]\]                12                  50.6              26.0                9.4                      1.7                         38.2                     NR                  Metformin                             Sitagliptin 100 mg qd      21                                         Glimepiride 2 mg qd                          21                                         ✓         
  Pérez- Monteverde 2011 \[[@pone.0236603.ref051]\]   12                  51.1              29.8                9.1                      3.2                         NR                       NR                  No                                    Sitagliptin 100 mg qd      244                                        Pioglitazone 15--30 mg qd                    248                                        ✓         ✓
  Pratley 2011 \[[@pone.0236603.ref052]\]             52                  55.5              32.6                8.5                      6.2                         NR                       NR                  Metformin                             Sitagliptin 100 mg qd      219                                        Liraglutide 1.2 mg qd                        225                                        ✓         ✓
  Pratley 2018 \[[@pone.0236603.ref060]\]             26                  55.1              31.6                8.6                      6.8                         50.4                     NR                  Metformin                             Sitagliptin 100 mg qd      247                                        Ertugliflozin 15 mg qd                       248                                        ✓         
  Rosenstock 2012 \[[@pone.0236603.ref053]\]          12                  52.0              31.6                7.7                      5.8                         62.2                     NR                  Metformin                             Sitagliptin 100 mg qd      65                                         Canagliflozin 300 mg qd                      64                                         ✓         
  Schernthaner 2013 \[[@pone.0236603.ref054]\]        52                  56.7              31.6                8.1                      9.6                         54.6                     0.60                Metformin + sulfonylurea              Sitagliptin 100 mg qd      378                                        Canagliflozin 300 mg qd                      377                                        ✓         ✓
  Scott 2007 \[[@pone.0236603.ref043]\]               12                  54.9              30.5                7.9                      4.5                         51.9                     NR                  OHA (except for thiazolidinediones)   Sitagliptin 50 mg bid      124                                        Glipizide 5--20 mg qd                        123                                        ✓         
  Scott 2008 \[[@pone.0236603.ref042]\]               18                  55.0              30.3                7.8                      4.8                         62.7                     0.34                Metformin                             Sitagliptin 100 mg qd      94                                         Rosiglitazone 8 mg qd                        87                                         ✓         ✓
  Seck 2010 \[[@pone.0236603.ref044]\]                104                 57.3              31.1                7.3                      5.8                         59.5                     0.31                Metformin                             Sitagliptin 100 mg qd      248                                        Glipizide 5--20 mg qd                        256                                        ✓         ✓
  Shi 2019 \[[@pone.0236603.ref064]\]                 12                  42.2              26.5                11.3                     0                           NR                       NR                  Metformin + insulin                   Sitagliptin 100 mg qd      35                                         Voglibose 0.2 mg tid                         35                                         ✓         
  Takihata 2013 \[[@pone.0236603.ref055]\]            24                  60.5              25.2                7.4                      NR                          35.7                     NR                  Metformin and/or sulfonylurea         Sitagliptin 50 mg qd       58                                         Pioglitazone 15 mg qd                        57                                         ✓         
  Tsurutani 2018 \[[@pone.0236603.ref061]\]           12                  53.7              28.7                7.5                      3                           71.3                     NR                  NR                                    Sitagliptin 50 mg qd       59                                         Ipragliflozin 50 mg qd                       60                                         ✓         ✓
  Weinstock 2015 \[[@pone.0236603.ref062]\]           104                 54.0              31.0                8.2                      7.0                         NR                       NR                  Metformin and/or another OHA          Sitagliptin 100 mg qd      315                                        Duraglutide 0.75 mg qd                       302                                        ✓         
  Williams- Herman 2010 \[[@pone.0236603.ref056]\]    104                 55.1              31.4                8.6                      3.9                         44.0                     0.39                No                                    Sitagliptin 100 mg qd      52                                         Metformin 500 mg bid                         65                                         ✓         ✓
  Yokoh 2015 \[[@pone.0236603.ref063]\]               24                  58.5              26.1                7.6                      6.8                         44.4                     NR                  Metformin or pioglitazone             Sitagliptin 50 mg qd       58                                         Voglibose 0.2 mg tid or miglitol 50 mg tid   58                                         ✓         ✓
  Iwamoto 2010 \[[@pone.0236603.ref065]\]             12                  59.1              24.9                7.6                      5.4                         31.7                     NR                  No                                    Vildagliptin 50 mg bid     188                                        Voglibose 0.2 mg tid                         192                                        ✓         
  Kim 2017 \[[@pone.0236603.ref066]\]                 12                  56.0              25.9                7.6                      6.1                         55.5                     NR                  Metformin                             Vildagliptin 50 mg bid     17                                         Glimepiride 2 mg qd                          17                                         ✓         
  Sawayama 2013 \[[@pone.0236603.ref067]\]            26                  68.4              26.2                7.4                      NR                          38.8                     NR                  Glimepiride                           Vildagliptin 50 mg qd      11                                         Glimepiride 1--2 mg qd                       12                                         ✓         
  Takeshita 2015 \[[@pone.0236603.ref068]\]           12                  64.7              24.7                8.0                      NR                          25.5                     NR                  Sitagliptin                           Vildagliptin 50 mg bid     58                                         Liraglutide 0.3--0.9 mg qd                   54                                         ✓         

Abbreviations: BMI, body mass index; DPP-4, dipeptidyl peptidase-4; HbA1c, glycosylated hemoglobin A1c; HOMA-β, homeostatic model of assessment for beta-cell function; NR, not reported; OHA, oral hypoglycemic agents; PIR, proinsulin-to-insulin ratio; T2DM, type 2 diabetes mellitus; qd, once daily; bid, twice daily; tid, three times daily; qw, once weekly.

Comparison of DPP-4 inhibitors with other hypoglycemic drugs using HOMA-β as biomarker {#sec012}
--------------------------------------------------------------------------------------

Relevant data for comparing the effect on HOMA-β between DPP-4 inhibitors and other hypoglycemic drugs were available from eight studies of α-GIs \[[@pone.0236603.ref030], [@pone.0236603.ref031], [@pone.0236603.ref035], [@pone.0236603.ref041], [@pone.0236603.ref050], [@pone.0236603.ref063]--[@pone.0236603.ref065]\], five studies of GLP-1 analogues \[[@pone.0236603.ref047], [@pone.0236603.ref052], [@pone.0236603.ref058], [@pone.0236603.ref062], [@pone.0236603.ref068]\], five studies of metformin \[[@pone.0236603.ref029], [@pone.0236603.ref038], [@pone.0236603.ref039], [@pone.0236603.ref040], [@pone.0236603.ref056]\], five studies of SGLT2 inhibitors \[[@pone.0236603.ref036], [@pone.0236603.ref053], [@pone.0236603.ref054], [@pone.0236603.ref060], [@pone.0236603.ref061]\], ten studies of sulfonylureas \[[@pone.0236603.ref037], [@pone.0236603.ref043], [@pone.0236603.ref044]--[@pone.0236603.ref046], [@pone.0236603.ref048], [@pone.0236603.ref057], [@pone.0236603.ref059], [@pone.0236603.ref066], [@pone.0236603.ref067]\], and four studies of thiazolidinediones \[[@pone.0236603.ref042], [@pone.0236603.ref049], [@pone.0236603.ref051], [@pone.0236603.ref055]\] ([Table 1](#pone.0236603.t001){ref-type="table"}). According to the results of Cochrane's Q test, the random effects model was employed for the meta-analysis of DPP-4 inhibitors versus α-GIs, SGLT2 inhibitors and sulfonylureas, but the fixed effects model was employed for DPP-4 inhibitors versus the remaining comparators. Analysis of all 37 studies showed that DPP-4 inhibitors increased HOMA-β to a significantly greater extent than α-GIs \[WMD (95% CI): 7.54% (3.84, 11.24%)\]. In contrast, DPP-4 inhibitors increased HOMA-β to a significantly less extent than GLP-1 analogues \[-13.08% (-14.11, -12.05%)\]. No significant differences in the change in HOMA-β were observed between DPP-4 inhibitors and metformin \[-2.18% (-10.48, 6.12%)\], between DPP-4 inhibitors and SGLT2 inhibitors \[-4.08% (-11.65, 3.48%)\], between DPP-4 inhibitors and sulfonylureas \[-14.18% (-29.80, 1.45%)\], and between DPP-4 inhibitors and thiazolidinediones \[6.63% (-1.55, 14.81%)\] ([Fig 2](#pone.0236603.g002){ref-type="fig"}).

![Forest plots of meta-analyses for changes in homeostatic model of assessment for beta-cell function (HOMA-β).\
Filled square represents weighted mean difference (WMD) of homeostatic model of assessment for beta-cell function (HOMA-β) for dipeptidyl peptidase-4 inhibitor versus other hypoglycemic agents. The two ends of the horizontal line passing through WMD represent the lower and upper limits of 95% confidence interval (CI). The size of each square corresponds to the weight assigned to the specific WMD data in the meta-analysis. Filled diamond at the bottom of each forest plot shows the combined WMD for individual comparison. Lateral tips of the diamond represent the lower and upper limits of 95% CI. A diamond located to the right of y-axis favors DPP-4 inhibitors over comparators. Abbreviations: CI, confidence interval; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; IV, inverse variance; SD, standard deviation; SGLT2, sodium-glucose cotransporter 2; alo, alogliptin; ana, anagliptin; saxa, saxagliptin; sita, sitagliptin; vilda, vildagliptin.](pone.0236603.g002){#pone.0236603.g002}

Comparison of DPP-4 inhibitors with other hypoglycemic drugs using PIR as biomarker {#sec013}
-----------------------------------------------------------------------------------

Relevant data for comparing the effect on PIR between DPP-4 inhibitors and other hypoglycemic drugs were available from four studies of α-GIs \[[@pone.0236603.ref031], [@pone.0236603.ref034], [@pone.0236603.ref050], [@pone.0236603.ref063]\], one study of a GLP-1 analogue \[[@pone.0236603.ref052]\], four studies of metformin \[[@pone.0236603.ref029], [@pone.0236603.ref039], [@pone.0236603.ref040], [@pone.0236603.ref056]\], two studies of SGLT2 inhibitors \[[@pone.0236603.ref054], [@pone.0236603.ref061]\], seven studies of sulfonylureas \[[@pone.0236603.ref032], [@pone.0236603.ref033], [@pone.0236603.ref044]--[@pone.0236603.ref046], [@pone.0236603.ref048], [@pone.0236603.ref057]\], and three studies of thiazolidinediones \[[@pone.0236603.ref042], [@pone.0236603.ref049], [@pone.0236603.ref051]\] ([Table 1](#pone.0236603.t001){ref-type="table"}). In accordance with the results of Cochrane Q test, the random effects model was employed for the comparison with sulfonylureas, and the fixed effects model for comparisons with all other drugs. Analysis of all 21 studies showed that DPP-4 inhibitors reduced PIR to a significantly greater extent than α-GIs \[WMD (95%CI): -0.04 (-0.07, -0.02)\] and SGLT2 inhibitors \[-0.08 (-0.14, -0.03)\]. In contrast, GLP-1 analogues and metformin reduced PIR to a significantly greater extent than DPP-4 inhibitors \[0.06 (0.00, 0.12) and 0.04 (0.02, 0.06), respectively\]. No statistically significant differences were detected for the comparisons of DPP-4 inhibitors with sulfonylureas \[-0.02 (-0.05, 0.01)\], and with thiazolidinediones \[-0.01 (-0.05, 0.02)\] ([Fig 3](#pone.0236603.g003){ref-type="fig"}).

![Forest plots of meta-analyses for changes in proinsulin-to-insulin ratio (PIR).\
Filled square represents weighted mean difference (WMD) of proinsulin-to-insulin ratio (PIR) for dipeptidyl peptidase-4 inhibitor versus other hypoglycemic agents. The two ends of the horizontal line passing through WMD represent the lower and upper limits of 95% confidence interval (CI). The size of each square corresponds to the weight assigned to the specific WMD data in the meta-analysis. Filled diamond at the bottom of each forest plot shows the combined WMD for individual comparison. Lateral tips of the diamond represent the lower and upper limits of 95% CI. A diamond located to the left of y-axis favors DPP-4 inhibitors over comparators. Abbreviations: CI, confidence interval; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; IV, inverse variance; SD, standard deviation; SGLT2, sodium-glucose cotransporter 2; alo, alogliptin; ana, anagliptin; lina, linagliptin; sita, sitagliptin.](pone.0236603.g003){#pone.0236603.g003}

Two-dimensional display for the effects of DPP-4 inhibitors versus other hypoglycemic drugs using HOMA-β and PIR as biomarkers {#sec014}
------------------------------------------------------------------------------------------------------------------------------

[Fig 4](#pone.0236603.g004){ref-type="fig"} showed a two-dimensional plot depicting WMDs with 95% CIs obtained from comparisons of DPP-4 inhibitors versus other classes of hypoglycemic drugs using HOMA-β and PIR as biomarkers. The data of each pair of comparison appeared as a cluster in one of the four quadrants. Numerical results of each comparison between DPP-4 inhibitors and other classes of hypoglycemia drugs already mentioned above. [Fig 4](#pone.0236603.g004){ref-type="fig"} showed those results in an integrated manner to facilitate visual understanding. When both perpendicular and horizontal lines were present within the second quadrant, HOMA-β and PIR consistently showed superiority of DPP-4 inhibitors compared with other classes of hypoglycemic drugs. Whereas, when both perpendicular and horizontal lines were present within the fourth quadrant, HOMA-β and PIR consistently showed inferiority of DPP-4 inhibitors.

![Two-dimensional display of comparisons of DPP-4 inhibitors versus other hypoglycemic drugs using HOMA-β and PIR.\
Combined weighted mean differences (WMDs) of homeostatic model of assessment for beta-cell function (HOMA-β) for various comparisons are plotted on the ordinate, and combined WMDs of proinsulin-to-insulin ratio (PIR) are plotted on the abscissa. The center of each circle represents the combined WMD of HOMA-β and PIR. Perpendicular and horizontal lines represent 95% confident intervals for HOMA-β and PIR, respectively. Approximate number of patients in the sample is shown by the area of the circle. Note that an increase in HOMA-β and a decrease in PIR are associated with amelioration of beta-cell function in patients with type 2 DM. Abbreviations: DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HOMA-β, homeostatic model of assessment for beta-cell function; PIR, proinsulin-to-insulin ratio; SGLT2, sodium-glucose cotransporter 2.](pone.0236603.g004){#pone.0236603.g004}

Sensitivity analysis and evaluation of publication bias {#sec015}
-------------------------------------------------------

We conducted a separate meta-analysis after excluding 11 studies \[[@pone.0236603.ref035], [@pone.0236603.ref038], [@pone.0236603.ref050], [@pone.0236603.ref052], [@pone.0236603.ref055], [@pone.0236603.ref057], [@pone.0236603.ref059], [@pone.0236603.ref061], [@pone.0236603.ref063], [@pone.0236603.ref066], [@pone.0236603.ref068]\], since they appeared to have high risk of bias according to Cochrane's bias tool ([S3 Table](#pone.0236603.s005){ref-type="supplementary-material"}). Excluding those studies changed the significance of the difference in HOMA-β for DPP-4 inhibitors versus SGLT2 inhibitors \[-7.82% (-11.89, -3.75%)\] and versus sulfonylureas \[-18.70% (-36.86, -0.53%)\].

Funnel plots of the comparisons of DPP-4 inhibitors versus α-GIs, SGLT2 inhibitors, and sulfonylureas for HOMA-β ([S1A, S1D and S1E Fig](#pone.0236603.s001){ref-type="supplementary-material"}) as well as those of DPP-4 inhibitors versus α-GIs and sulfonylureas for PIR ([S2A and S2D Fig](#pone.0236603.s002){ref-type="supplementary-material"}) displayed apparently asymmetric distribution of data. However, the 95% CIs of the intercepts of Egger's regression lines \[[@pone.0236603.ref028]\] for HOMA-β between DPP-4 inhibitors and α-GIs \[(-1.50, 3.47), p = 0.37\], SGLT2 inhibitors \[(-2.33, 9.37), p = 0.15\] or sulfonylureas \[(-5.71, 4.67), p = 0.82\]; as well as for PIR between DPP-4 inhibitors and α-GIs \[(-6.77, 3.72), p = 0.34\] or sulfonylureas \[(-4.27, 1.50), p = 0.27\] included the origin of the coordinates. As a result, we concluded that sensitivity analysis of meta-analysis to evaluate the effect of publication bias may not be required for either HOMA-β or PIR.

Discussion {#sec016}
==========

To the best of our knowledge, the present study is the first to compare the pancreatic beta-cell preserving effect between DPP-4 inhibitors and other hypoglycemic drugs using two distinct biomarkers, HOMA-β and PIR. In this study, the results of HOMA-β and PIR consistently showed superiority of DPP-4 inhibitors over α-GIs and inferiority of DPP-4 inhibitors to GLP-1 analogues. However, PIR showed inferiority of DPP-4 inhibitors to metformin and superiority over SGLT2 inhibitors, while HOMA-β showed no significant differences in these comparisons. On the other hand, no significant differences in the change in both HOMA-β and PIR were observed between DPP-4 inhibitors and sulfonylureas as well as between DPP-4 inhibitors and thiazolidinediones. Recently, Wu et al. \[[@pone.0236603.ref069]\] reported a network meta-analysis on the comparisons of incretin-based therapies (i.e. DPP-4 inhibitors and GLP-1 analogues) with α-GIs, metformin, sulfonylureas, thiazolidinediones and placebo using HOMA-β as the sole biomarker for beta-cell function in patients with type 2 DM. Their results agree well with our present meta-analysis. The implication of our study is that results of comparison of beta-cell preserving effect between DPP-4 inhibitors and other hypoglycemic drugs using HOMA-β and PIR as biomarker should be interpreted with caution, because the two biomarkers may indicate different functions of beta-cell.

The changes observed in WMDs for HOMA-β and PIR yielded comparable results in the comparisons between DPP-4 inhibitors and two hypoglycemic drugs; α-GIs and GLP-1 analogues, in patients with type 2 DM. These results suggest that DPP-4 inhibitors are superior to α-GIs but inferior to GLP-1 analogues in terms of beta-cell preserving effect. In our meta-analysis between DPP-4 inhibitors and α-GIs using all the retrieved articles, we included a study in which all participants were given insulin \[[@pone.0236603.ref064]\]. Nevertheless, removal of that study \[[@pone.0236603.ref064]\] from meta-analysis did not change the statistical results.

On the other hand, the changes observed in WMDs for HOMA-β and PIR when comparing DPP-4 inhibitors and sulfonylureas showed opposite trends: the changes in HOMA-β appeared to favor sulfonylureas over DPP-4 inhibitors, whereas those in PIR appeared opposite. Hyperglycemia in patients with type 2 DM may be attributed to reduced insulin secretion from the pancreas and/or to peripheral insulin resistance. Attenuated basal secretion of insulin which is stimulated mainly by fasting serum glucose levels can be detected by HOMA-β \[[@pone.0236603.ref070]\]. However, insulin secretion in patients receiving sulfonylureas may be augmented even during euglycemia by the pharmacological effects of the drugs \[[@pone.0236603.ref071]\]. As a result, increases of HOMA-β observed after the initiation of sulfonylurea may not be attributed simply to the beta-cell preserving effect of the drug \[[@pone.0236603.ref072]\]. In our study, the comparison between DPP-4 inhibitors and sulfonylureas using HOMA-β as biomarker did not reach a significant level. One of the reasons for this result may be the selection of statistical model. We employed the random effect model, since the data reported by Derosa et al. \[[@pone.0236603.ref048]\] showed a heterogenously large effect on HOMA-β. Indeed, when their data were removed from the comparative integration analysis, heterogeneity disappeared and the overall comparison was statistically significant. The heterogenous data of Derosa et al. were probably due to markedly higher baseline HOMA-β in their patients (93.0%) compared to other studies used in comparison (range: 38.2% to 67.5%). In contrast, there was no significant difference in baseline PIR between the study of Derosa et al (0.25) and the other studies (range: 0.20 to 0.49). PIR is associated with the efficiency of proinsulin processing to insulin within beta-cells rather than the beta-cell mass \[[@pone.0236603.ref012]\]. In this respect, PIR may be a more suitable biomarker than HOMA-β for assessing the beta-cell function in patients with type 2 DM receiving sulfonylureas. In the present study, no significant differences were observed between DPP-4 inhibitors and sulfonylureas when using HOMA-β or PIR, although there was a trend of superiority for DPP-4 inhibitors over sulfonylureas when using PIR.

HOMA-β and PIR showed discrepant results in the assessment of beta-cell preserving effects of SGLT2 inhibitors. HOMA-β was proposed as a marker of beta-cell function on the assumption that blood glucose level depends only the rate of insulin secretion rate \[[@pone.0236603.ref022]\]. In patients receiving SGLT2 inhibitors, however, blood glucose levels are controlled not only by the insulin-dependent intracellular transport but also by the SGLT2 inhibitor-induced augmentation of urinary loss of glucose \[[@pone.0236603.ref073]\]. Consequently, the effect of SGLT2 inhibitors on beta-cell preservation may be overestimated by HOMA-β. The other biomarker examined in this study, PIR, was employed in a recent large cohort study searching for clinical factors that influence the progression of pancreatic beta-cell dysfunction (BetaDecline study) \[[@pone.0236603.ref074]\]. Taken together, PIR may be a useful biomarker of pancreatic beta-cell function for comparing DPP-4 inhibitors with SGLT2 inhibitors.

There are few studies on the effects of thiazolidinediones and metformin on beta-cell function in humans. Ishida et al. \[[@pone.0236603.ref075]\] reported that pioglitazone enhanced beta-cell function in diabetic mice through reduction of oxidative stress in pancreatic beta-cells. It has been reported that the reduction of oxidative stress could be due to increase the intrinsic activity of the glucose transporters \[[@pone.0236603.ref076]\] or augmented beta-cell pancreatic duodenal homeobox-1 expression \[[@pone.0236603.ref077]\]. Meanwhile, the favorable effects of metformin for beta-cell function are considered to be partially based on improving insulin processing insufficiency. Nagi et al. \[[@pone.0236603.ref078]\] reported that metformin decreased plasma proinsulin concentrations in subjects with type 2 diabetes mellitus. Their findings support the results of our meta-analysis that metformin reduced PIR to a significantly greater extent than DPP-4 inhibitors. However, precise mechanisms by which thiazolidinediones and metformin improve beta-cell function in clinical settings remain to be clarified.

In the present study, we made a new comprehensive attempt to compare the beta-cell preserving effects of hypoglycemic drugs using HOMA-β and PIR as biomarkers. We present a two-dimensional display of the beta-cell preserving effect of DPP-4 inhibitors versus other hypoglycemic drugs when assessed by HOMA-β and PIR ([Fig 4](#pone.0236603.g004){ref-type="fig"}). While an increase in HOMA-β may be associated with amelioration of the beta-cell function of insulin secretion \[[@pone.0236603.ref011]\], a reduction in PIR may be related to the improvement of proinsulin processing to insulin \[[@pone.0236603.ref079]\]. Therefore, data plotted in either the second or fourth quadrant imply qualitative similarity of HOMA-β and PIR in assessing the beta-cell function preserving effect of hypoglycemic drugs. We revealed that there is an agreement between HOMA-β and PIR regarding the pancreatic beta-cell preserving effects of hypoglycemic drugs compared with DPP-4 inhibitors, except for sulfonylureas and SGLT2 inhibitors for which the assumption of HOMA-β may not hold. In the plot of HOMA-β versus PIR in [Fig 4](#pone.0236603.g004){ref-type="fig"}, comparisons between DPP-4 inhibitors and sulfonylureas or SGLT2 inhibitors are plotted in the third quadrant. Therefore, evaluation using HOMA-β alone might not be suitable. Data presentation as [Fig 4](#pone.0236603.g004){ref-type="fig"} may be useful for comprehensive interpretation of the pancreatic beta cell function preserving effects of hypoglycemic drugs with different mechanisms of action. Further studies using this approach to compare the performance of different biomarkers of pancreatic beta-cells are anticipated.

HOMA-β is most frequently used as a clinical and epidemiological biomarker for assessing pancreatic beta-cell function. However, our results of comparison between DPP-4 inhibitors and sulfonylureas or SGLT2 inhibitors illustrate that HOMA-β may not reflect beta-cell function accurately for drugs with hypoglycemic actions via direct insulin secretion or independent of insulin secretion. In addition, although HOMA-β assumes that all glucose-lowering action is provided by correctly processed insulin derived from beta-cells \[[@pone.0236603.ref080]\], impaired processing of proinsulin to insulin is observed in patients with type 2 DM \[[@pone.0236603.ref081]\].

One of the limitations of the present study is inherent to the methodology of meta-analysis. The biomarkers employed for evaluating the functional beta-cell reserve; HOMA-β and PIR, were secondary endpoints of the clinical trials included in the present meta-analysis. While the Cochrane risk of bias tool may be useful for assessing the quality of studies and the primary outcome, whether it is also valid for assessing the quality of the secondary outcome remains unclear. In particular, when the data of secondary outcomes are derived from a subgroup of patients, random allocation of patients may not be guaranteed. As a result, we cannot categorically eliminate selection bias or attrition bias for the assessment of the secondary outcomes analyzed in the present study. In addition, we cannot eliminate publication bias legitimately from meta-analysis despite the performance of funnel plot analyses. Furthermore, Egger's regression analysis used for assessing bias and homogeneity of studies may be useful if more than ten publications are available for each integration analysis \[[@pone.0236603.ref082]\].

Conclusions {#sec017}
===========

We performed comprehensive meta-analyses of the effects of DPP-4 inhibitors on pancreatic beta-cell function compared with other classes of hypoglycemic drugs using HOMA-β and PIR as biomarkers. DPP-4 inhibitors appear to be superior to α-GIs but inferior to GLP-1 analogues in terms of preservation of beta-cell function assessed by either HOMA-β or PIR. DPP-4 inhibitors seem to be superior to SGLT2 inhibitors but inferior to metformin in terms of islet function assessed only by PIR. Since HOMA-β and PIR may represent different aspects of beta-cell function, results of comparison of beta-cell function preserving effects among hypoglycemic agents should be interpreted with caution.

Supporting information {#sec018}
======================

###### Funnel plots of the data employed in the meta-analysis of homeostatic model of assessment for beta-cell function (HOMA-β).

This plot is effect size (weighted mean difference of homeostatic model of assessment for beta-cell function \[HOMA-β\] from individual articles) (X axis) versus standard error of effect size (Y axis). Dotted vertical line represents pooled estimate of effects. Abbreviations: DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; MD, mean difference; SE, standard error; SGLT2, sodium-glucose cotransporter 2.
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###### Funnel plots of the data employed for the meta-analysis of proinsulin-to-insulin ratio (PIR).

This plot is effect size (weighted mean difference of proinsulin-to-insulin ratio \[PIR\] from individual articles) (X axis) versus standard error of effect size (Y axis). Dotted vertical line represents pooled estimate of effects. Abbreviations: DPP-4, dipeptidyl peptidase-4; MD, mean difference; SE, standard error; SGLT2, sodium-glucose cotransporter 2.

(TIF)
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Authors' responses to Reviewer \#1 and Reviewer \#2

1\. We have made our responses to reviewers' comments and indicated their corresponding revisions in text with page and line numbers in "Revised Article with Changes Highlighted" file.

2\. For responding to the comment 3 from Reviewer \#2, we have added the data as a S2 Table. As a result, we have renumbered supplemental Tables.

3\. According to the revisions made in the original manuscript, the reference 80 and subsequent ones were renumbered.

4\. Pages in S1 Table were renumbered, according to the revisions made in the manuscript.

5\. Except for page and line numbers shown below, we have revised the manuscript according to proofreading.

6\. We have used the following abbreviations in this text: DPP-4, dipeptidyl peptidase-4; HOMA-β, homeostatic model of assessment for beta-cell function; PIR, proinsulin-to-insulin ratio; SGLT2, sodium-glucose cotransporter 2

Authors' response to Reviewer \#1:

Comment: My concern is about use of HOMA parameters in general. As discussed in ref. 8, HOMA-beta shows activity of beta-cells but never health status of beta-cell. An increased HOMA-beta in SU users is sometimes mistakenly interpreted. The data in this MS clearly showed this fact. Authors should discuss the abuse of HOMA modeling in DISCUSSION.

Response: We thank Reviewer \#1's important comment. According to his/her comment, we have added the explanations about the abuse of HOMA-β in general citing comparative results between DPP-4 inhibitors and sulfonylureas or SGLT2 inhibitors as examples (pp. 28-29, lines 423-430).

Authors' responses to Reviewer \#2:

We deeply appreciate Reviwer \#2's comments. We would like to answer to his/her comments as follows.

Comment 1: As described in the abstract, the aim of this study was to compare the effects of DPP-4 inhibitors and other classes of hypoglycemic drugs on HOMA-β and PIR. However, the conclusion highlighted the application of HOMA-β and PIR rather than the special effects of DPP-4 on HOMA-β and PIR relative to other drugs. The conclusion seems to be beyond the major purpose of the study.

Response: We agree with Reviewer \#2's comment. We have revised the conclusion of abstract so that we have described the answer corresponding to the aim of the study (p. 3, lines 41-46). In addition, we have revised the discussion and conclusion of the main text to clarify the point of our study (pp. 23-24, lines 333-336; p. 24, lines 343-345; p. 26, lines 377-378; pp. 26-27, lines 387-388; p. 30, lines 448-454).

Comment 2: Why didn't authors include the Embase in the literature search?

Response: For reducing potential biases (mainly selection bias), we performed literature search of meta-analysis using multiple databases. MEDLINE and EMBASE are two major databases for systematic literature search. Halladay CW (J Clin Epidemiol. 2015;68(9):1076) and Slobogean GP (J Clin Epidemiol. 2009;62(12):1261) reported that EMBASE may give additional information to those of MEDLINE. Slobogean also reported that the CENTRAL database may be useful for increasing relevant literature in addition to MEDLINE and EMBASE. Therefore, we have recognized that we could perform a systematic literature search through using MEDLINE, CENTRAL and Ichushi-web.

Comment 3: Please show the detailed search strategies.

Response: We have added the detailed search strategies for the MEDLINE, CENTRAL and Ichushi-web databases in S2 Table. In addition, we have described these revisions in text (p. 6, lines 90-91).

Comment 4: Why didn't authors exclude the study in which background medications include insulin? For example, Shi C 2019 (Reference 64). The use of exogenous insulin may lead to incorrect values of HOMA-β and PIR.

Response: As Reviewer \#2 pointed out, the administration of exogenous insulin (and other medications) may influence on HOMA-β and PIR values. However, we performed our meta-analysis with studies performed with the randomized design to even out the impact of the bias deriving from various background medications. It was difficult to eliminate or evaluate completely the effects of exogenous insulin or other medications, because the curated studies did not report all the medications including insulin for rescue use. Furthermore, we found little impact on the results of our study by removing the Reference 64: WMD of HOMA-β \[95% CI\] for the original data vs. that without the Reference 64 were 7.54% \[3.84, 11.24%\] and 6.78% \[4.78, 8.78%\], respectively. In this context, we have added a comment about influence of exogenous insulin to our results (p. 24, lines 345-348).

Comment 5: In the introduction, authors posed two questions: whether these incretin-related drugs have advantage over other hypoglycemic drugs by exhibiting pancreatic beta-cell function preserving effect; whether there are different effects of beta-cell function preservation between DPP-4 inhibitors and other classes of hypoglycemic drugs using both HOMA-β and PIR as biomarkers. In the discussion, however, authors mainly discussed the advantage and/or disadvantage of HOMA-β and PIR as the biomarkers to assess the effect of various hypoglycemic agents on the beta-cell function in the discussion. Therefore, has the study already answered the questions posed in the introduction?

Response: We agree with Reviewer \#2 that we did not answered directly the questions we posed in the introduction. According to the comment, we have revised the first paragraph of introduction section so that we clearly described that the aim of the present study was to compare the effects of DPP-4 inhibitors with other hypoglycemic drugs (p. 4, lines 55-61, including revision of Reference 5-7). We also agree with the other comment that the discussion about advantage and disadvantage of HOMA-β and PIR as biomarkers of the pancreatic beta-cell function may be beyond the range of the present study. We might have discussed too much about the physiological aspects of the two biomarkers. However, we consider that our descriptions would have been needed for facilitating understanding our data to general readers who do not have deep knowledge about the two biomarkers.

Comment 6: What is the criterion to determine whether or not HOMA-β or PIR is a suitable biomarker for comparisons of beta-cell function preserving effect between hypoglycemic drugs with different mechanisms of action?

Response: We agree with Reviewer \#2 that the criterion might be useful to determine either HOMA-β or PIR as a better biomarker for assessing the pancreatic beta-cell preserving effects of different hypoglycemic drugs. We do not have a comprehensive and absolute criterion about the choice of biomarkers, since we performed only pair-wise comparison in the present study. Instead, we made Fig 4 for helping the understanding of our data. Inconsistent results between HOMA-β and PIR may be useful information about the two biomarkers. For example, we may say that HOMA-β overestimates the effects of sulfonylureas (p. 25, lines 354-359) and SGLT2 inhibitors (p. 26, lines 379-384) on beta-cell function, and PIR would be a useful biomarker for these drugs.

Comment 7: According to the meta-analysis, if HOMA-β and PIR are used together to assess the effect of various hypoglycemic drugs on beta-cell function preservation, how would the results be explained? Namely, should be the results of HOMA-β and PIR consistent or not? If consistent, what does it suggest? If inconsistent, what does it suggest? For different hypoglycemic drugs, how to appropriately use HOMA-β and PIR?

Response: We agree with Reviewer \#2's thoughtful comment. We consider that secretion of insulin assessed by HOMA-β and processing of proinsulin assessed by PIR may represent different aspects of beta-cell functions (pp. 4-5, lines 66-68). The selection of one biomarker over the other depends on the mechanism of hypoglycemic action of drugs to be compared. If the results of HOMA-β and PIR are consistent, we may say the advantage of one drug over the other comprehensively (p. 24, lines 343-345). However, if the results are inconsistent, we may look for the reasons according to the pharmacological mechanisms of the respective drugs (pp. 26-27, lines 376-388; p. 27, lines 396-403).

Comment 8: English needs revision. Some linguistic errors have been made. A final check of the language by a native English speaking person may lead to the necessary improvements.

Response: We have asked the proofreading of the revised manuscript to another native English speaker.

###### 

Submitted filename: Response to reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0236603.r003

Decision Letter 1

Shimosawa

Tatsuo

Academic Editor

© 2020 Tatsuo Shimosawa

2020

Tatsuo Shimosawa

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

10 Jul 2020

Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: a meta-analysis

PONE-D-20-13427R1

Dear Dr. Takahashi,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once you change Line 344:  Replacing \'pancreatic preserving effect\' with \'beta-cell preserving effect' and it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Tatsuo Shimosawa, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: The authors did a good job and further improved the manuscript in which the reviewer's comments were adequately answered. A minor revision was suggested as below:

Line 344: Suggest replacing \'pancreatic preserving effect\' with \'beta-cell preserving effect'.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pone.0236603.r004

Acceptance letter

Shimosawa

Tatsuo

Academic Editor

© 2020 Tatsuo Shimosawa

2020

Tatsuo Shimosawa

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

14 Jul 2020

PONE-D-20-13427R1

Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: a meta-analysis

Dear Dr. Takahashi:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Tatsuo Shimosawa

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
